News
Xarelto Approval Expands to Symptomatic PAD After Revascularization
The approval was based on data from the phase 3 VOYAGER PAD study.
Your search for rivaroxaban returned 148 results
Case Studies
Miscommunication Leads to Duplicate Anticoagulation Therapy for Patient
In a recent case study in Case Reports - Drug Safety, miscommunication between pharmacists leads to unintentional duplicate anticoagulation therapy and elevated INR in a patient with a history of pulmonary embolism (PE).
News
Rivaroxaban Tied to Lower Brain Bleed Risk in A-Fib
A once daily oral dose of rivaroxaban (Xarelto) significantly lowers the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) at moderate to high risk of stroke.
News
Food Type, Timing Has No Clinically Relevant Impact on Rivaroxaban
Currently, the prescribing information recommends 20mg once daily with an evening meal for the AF indication, and 15mg twice daily with food for 21 days, followed by 20mg once daily with food for the remainder of treatment for the DVT/PE indications.
Drug News
Rivaroxaban and Liver Injury: Case Studies Add to Safety Questions
A case study reports on two patients that experienced severe liver injury onset during treatment with the oral anticoagulant rivaroxaban.
Drugs in the Pipeline
sNDAs Submitted for Xarelto for Treatment and Prevention of Recurrent Venous Thromboembolism
Janssen Research & Development announced that it has submitted supplemental New Drug Applications (sNDAs) to the FDA seeking approval for the use of Xarelto (rivaroxaban) to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent venous thromboembolism (VTE).
News
Severe Abnormal Uterine Bleeding Risk With Anticoagulant Therapy Examined
Study findings revealed an increased risk of surgical intervention in women exposed to rivaroxaban.
Drugs in the Pipeline
Rivaroxaban sNDA Submitted for Symptomatic Peripheral Artery Disease
The application is supported by data from the double-blind, placebo-controlled phase 3 VOYAGER PAD trial.
News
AHA: Similar Stroke Risk on Stopping Rivaroxaban, Warfarin
For moderate-risk to high-risk patients with atrial fibrillation (AF), temporary or permanent discontinuation of anticoagulants is associated with a high risk of stroke, which is similar for rivaroxaban-treated or warfarin-treated patients
Drugs in the Pipeline
Priority Review Granted for Xarelto for Treatment of DVT, PE, and Long-Term Prevention of Recurrent DVT and PE
Janssen Research & Development announced that the FDA has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) for Xarelto (rivaroxaban) seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
